A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
A phase 1/2 trial of LBL-034 for Injection in multiple myeloma, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
Overview
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06049290 by Nanjing Leads Biolabs Co.,Ltd, with 342 participants planned, started 2023-10-20 and due to reach its primary completion in 2026-10-20. Interventions recorded: LBL-034 for Injection.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Shares Nanjing Leads Biolabs and the tag pipeline.
- TrialA Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Shares Nanjing Leads Biolabs and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Shares Nanjing Leads Biolabs and the tag pipeline.
- TrialA Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Shares Nanjing Leads Biolabs and the tag pipeline.